Table 4.
Effect of combinations of chemokine receptor-ligand gene polymorphism on acute or late acute rejection episodes
| (a) | |||||
|---|---|---|---|---|---|
| Polymorphism | |||||
| CCR2-V64I | MCP-1-2518 | ARa (%) | ORb | 95% C.I.c | P |
| G/G | AA/AG | 8/48 (16.7) | 1 | ||
| G/G | G/G | 12/25 (48.0) | 4.62 | 1.55–13.75 | 0.006 |
| GA/AA | AA/AG | 21/63 (33.3) | 2.50 | 0.99–6.29 | 0.052 |
| GA/AA | G/G | 11/30 (36.7) | 2.89 | 1.00–8.37 | 0.050 |
| (b) | |||||
|---|---|---|---|---|---|
| Polymorphism | |||||
| CCR2-V64I | MCP-1-2518 | LARa (%) | ORb | 95% C.I.c | P |
| G/G | AA/AG | 3/48 (6.3) | 1 | ||
| G/G | G/G | 8/25 (32.0) | 7.06 | 1.67–29.78 | 0.008 |
| GA/AA | AA/AG | 9/63 (14.3) | 2.50 | 0.64–9.80 | 0.188 |
| GA/AA | G/G | 6/30 (20.0) | 3.75 | 0.86–16.33 | 0.078 |
a
AR; acute rejection
b
OR; odds ratio
c
C.I.; confidence interval.
a
LAR; late acute rejection
b
OR; odds ratio
c
C.I.; confidence interval.